2024-10-25 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**1. Performance Comparison:**

Amgen Inc. (AMGN) has underperformed the S&P 500 (VOO) over the period considered. The cumulative return for AMGN is 76.54%, while the S&P 500 has returned 135.48%. This translates to a negative divergence of -58.94%, which falls within the 27.2 percentile range of historical divergence values. This indicates that AMGN's performance is currently in the lower range compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** 315.69
* **5-day Moving Average:** 316.93
* **20-day Moving Average:** 320.57
* **60-day Moving Average:** 325.38

AMGN is currently trading below all three moving averages, indicating a potential downtrend in the short to medium term. 

**3. Technical Indicators:**

* **RSI:** 43.75 – This suggests the stock is currently in a neutral territory, neither overbought nor oversold.
* **PPO:** -0.18 – A negative PPO indicates a possible bearish momentum.
* **Delta_Previous_Relative_Divergence:** -3.46 – This negative value signifies a recent decline in relative divergence.
* **Expected_Return:** 0.0 – The current expected return for AMGN is 0%, indicating a potential for future performance that matches the S&P 500. 

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue        |
|------------|---------|----------------|
| 2024-08-07 | 1.39    | 8.39 B$        |
| 2024-05-03 | -0.21   | 7.45 B$        |
| 2023-10-31 | 3.23    | 6.90 B$        |
| 2023-08-04 | 2.58    | 6.99 B$        |
| 2024-08-07 | 2.58    | 6.99 B$        |

The most recent earnings report for Q2 2024, released on August 7th, showed EPS of 1.39, exceeding the consensus estimate of 1.25. Revenue also beat expectations, reaching 8.39 B$ compared to the anticipated 8.32 B$. This positive earnings report signifies that AMGN is continuing to perform well despite market fluctuations.

**5. News and Recent Issues:**

**Recent Earnings News:**

* AMGN reported positive Q2 2024 earnings on August 7th, exceeding both EPS and revenue expectations. 
* Analysts have responded positively to the report, with several maintaining their "buy" ratings and raising price targets. 

**Recent Market Outlook:**

* FINBOLD analysts have highlighted AMGN as a strong player in the biotech sector, with a focus on its robust pipeline and potential for future growth.
* Several market analysts are predicting a potential growth in AMGN's stock price due to its strong earnings performance and its focus on innovative therapies.

**Analyst Opinions:**

* Most analysts are positive about AMGN's future prospects, citing its strong market position, pipeline development, and potential for growth in the biotech sector.
* However, there are some concerns surrounding the competitive landscape and potential for regulatory challenges.

**6. Overall Analysis:**

Although AMGN has underperformed the S&P 500 in the past, recent positive earnings results and a robust pipeline suggest a potential for future growth. The current technical indicators show mixed signals, with a neutral RSI and a slightly bearish PPO. The expected return of 0% suggests that AMGN is expected to perform similarly to the market in the long term. Investors should continue to monitor the company's performance and future announcements to make informed investment decisions.

**7. Conclusion:**

AMGN is a solid company with a strong position in the biotech sector. While it has faced some recent challenges, the positive earnings report and the company's focus on innovation suggest potential for future growth. Despite the current underperformance against the S&P 500, AMGN remains a compelling investment for long-term investors with a focus on the healthcare sector. 
